- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03925298
Recruitment Status Completed
First Posted April 24, 2019
Last update posted April 24, 2019
Elevated level of serum troponin (T-I) has been regarded as a prognostic biomarker of poor outcome in acute ischemic stroke. However, its role in outcome in thrombolysed ischemic stroke patients remains uncertain. The aim of this study was to evaluate the role of T-I as a predictive biomarker of short-term outcome in thrombolysed ischemic stroke participants.
Elevated level of serum troponin (T-I) has been regarded as a prognostic biomarker of poor outcome in acute ischemic stroke. However, its role in outcome in thrombolysed ischemic stroke patients remains uncertain. The aim of this study was to evaluate the role of T-I as a predictive biomarker of short-term outcome in thrombolysed ischemic stroke patients. Methods: This study included 72 acute ischemic stroke participants were treated with intravenous thrombolytic therapy. All participants were subjected to general and neurological evaluation including assessment of stroke severity using National Institute of Health Stroke Scale (NIHSS) at admission and investigations including measurement of serum level of T-I on admission. Outcome was assessed three months after stroke onset using NIHSS and modified Rankin scale (mRS).
Serum troponin I (T-I) was collected at hospital admission at the emergency department, before any treatment. Serum samples from patients were drawn using standard venipuncture techniques. Blood samples were left to clot for 4 hours at room temperature, then centrifuged to obtain the serum which was stored frozen at (-20C). Serum T-I levels were quantified in an enzyme-linked immune-sorbent assay technology (ELISA) following manufacturer's instructions (ALPCO, 26G Keewaydin Drive, Salem NH03079, USA). Upper reference limit for apparently healthy individuals is <0.01μg/l.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Participants were eligible for inclusion in the study if they had evidence suggesting
acute ischemic stroke that lasted for ≤ 4.5 hours .
- Those Participants were treated with intravenous thrombolytic therapy ((recombinant
tissue plasminogen activator (rt-PA)).
- Those who had hemorrhagic stroke
- participants presented with acute myocardial infarction, cerebrovascular stroke in the
previous three months.
- serious head trauma in the previous three months.
- urinary tract, lung, or gastrointestinal hemorrhage within the three weeks.
- serious trauma or major surgery within the previous two weeks.
- lumbar or arterial puncture at a non-compressible site within one week.
- those received heparin within 48 hours, resulting in an activated partial
thromboplastin time greater than the upper limit of normal.
- systolic pressure > 185 mmHg or diastolic pressure > 110 mmHg.
- blood glucose 400 mg/dL.
- current use of anticoagulants with an International Normalized Ratio > 1.7 or
prothrombin time>15 sec; platelet count 4.5 hours from the last time
known to be asymptomatic.
- those in whom troponin was not measured at admission were excluded from the study